Production (Stage)
Galmed Pharmaceuticals Ltd.
GLMD
$1.61
-$0.07-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 3.40M | 3.40M | 3.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 6.24M | 6.24M | 6.89M |
| Operating Income | -- | -- | -6.24M | -6.24M | -6.89M |
| Income Before Tax | -- | -- | -5.88M | -5.88M | -6.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -5.88 | -5.88 | -6.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -5.88M | -5.88M | -6.36M |
| EBIT | -- | -- | -6.24M | -6.24M | -6.89M |
| EBITDA | -- | -- | -6.15M | -6.15M | -6.86M |
| EPS Basic | -- | -- | -27.34 | -26.64 | -35.88 |
| Normalized Basic EPS | -- | -- | -15.63 | -15.19 | -20.97 |
| EPS Diluted | -- | -- | -27.34 | -26.64 | -35.88 |
| Normalized Diluted EPS | -- | -- | -15.63 | -15.19 | -20.97 |
| Average Basic Shares Outstanding | -- | -- | 1.37M | 1.52M | 1.14M |
| Average Diluted Shares Outstanding | -- | -- | 1.37M | 1.52M | 1.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |